Point72 Hong Kong’s Faeth Therapeutics FTH Stock Holding History

Point72 Hong Kong’s Portfolio FTH Stock Details FTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-39	Closed	-$4K	–	2284
2021 Q4	$4K	Buy	+39	New	+$5.83K	﹤0.01%	1746

Other funds holding FTH

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

DFO

Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Point72 Hong Kong's FTH Position: Q1 2022 in Review

Point72 Hong Kong sold out of Faeth Therapeutics (FTH) in Q1 2022, closing a stake of 39 shares — an estimated $4K sold.

Point72 Hong Kong first reported a position in FTH in Q4 2021 and held it in 1 quarter. The position peaked at $4K in Q4 2021. 42 funds tracked by Wall St. Rank hold FTH as of Q1 2022.

Point72 Hong Kong reported no remaining Faeth Therapeutics position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 39 Faeth Therapeutics shares in Q1 2022, an estimated $4K.
Point72 Hong Kong first reported a position in Faeth Therapeutics in Q4 2021 and held it in 1 quarter.
Point72 Hong Kong's Faeth Therapeutics position peaked at $4K in Q4 2021.
42 funds tracked by Wall St. Rank held Faeth Therapeutics as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.